ChimerDB/NN
-/:
Database/NN
of/IN
Chimeric/JJ
Sequences/NNS
in/IN
the/DT
GenBank/NN
./.
====================
Fusion/NN
proteins/NNS
resulting/VBG
from/IN
chimeric/JJ
sequences/NNS
are/VBP
excellent/JJ
targets/NNS
for/IN
therapeutic/JJ
drug/NN
development/NN
./.
====================
We/PRP
developed/VBD
a/DT
database/NN
of/IN
chimeric/JJ
sequences/NNS
by/IN
examining/VBG
the/DT
genomic/JJ
alignment/NN
of/IN
mRNA/NN
and/CC
EST/NN
sequences/NNS
in/IN
the/DT
GenBank/NN
./.
====================
We/PRP
identified/VBD
688/CD
chimeric/JJ
mRNA/NN
and/CC
20,998/CD
chimeric/JJ
EST/NN
sequences/NNS
./.
====================
Including/VBG
EST/NN
sequences/NNS
greatly/RB
expands/VBZ
the/DT
scope/NN
of/IN
chimeric/JJ
sequences/NNS
even/RB
though/IN
it/PRP
inevitably/RB
accompanies/VBZ
many/JJ
artifacts/NNS
./.
====================
Chimeric/JJ
sequences/NNS
are/VBP
clustered/VBN
according/VBG
to/TO
the/DT
ECgene/NN
ID/NN
so/RB
that/IN
the/DT
user/NN
can/MD
easily/RB
find/VBP
chimeric/JJ
sequences/NNS
related/JJ
to/TO
a/DT
specific/JJ
gene/NN
./.
====================
Alignments/NNS
of/IN
chimeric/JJ
sequences/NNS
are/VBP
displayed/VBN
as/IN
custom/JJ
tracks/VBZ
in/IN
the/DT
UCSC/NN
genome/NN
browser/JJR
./.
====================
ChimerDB/NN
,/,
available/JJ
at/IN
http/NN
:/:
//genome.ewha.ac.kr/ECgene/ChimerDB//JJ
,/,
should/MD
be/VB
a/DT
valuable/JJ
resource/NN
for/IN
finding/NN
drug/NN
targets/NNS
to/TO
treat/VB
cancers/NNS
./.
====================
Chromosomal/JJ
translocation/NN
is/VBZ
frequently/RB
observed/VBN
in/IN
many/JJ
hematologic/JJ
and/CC
solid/JJ
tumors/NNS
(/(
Mitelman/JJ
,/,
2000/CD
)/)
./.
====================
It/PRP
can/MD
affect/VB
the/DT
gene/NN
expression/NN
by/IN
disrupting/VBG
the/DT
promoter/NN
region/NN
of/IN
the/DT
gene/NN
or/CC
by/IN
joining/VBG
the/DT
gene/NN
with/IN
enhancer/NN
elements/NNS
like/IN
immunoglobulin/NN
or/CC
T-cell/NN
receptor/NN
genes/NNS
(/(
Croce/NN
et/FW
al./FW
,/,
1984/CD
)/)
./.
====================
However/RB
,/,
chromosomal/JJ
translocation/NN
in/IN
tumors/NNS
frequently/RB
creates/VBZ
a/DT
chimeric/JJ
mRNA/NN
sequence/NN
encoding/VBG
a/DT
fusion/NN
protein/NN
that/WDT
interferes/VBZ
the/DT
normal/JJ
====================
regulating/VBG
pathways/NNS
(/(
Mitelman/JJ
,/,
2000/CD
)/)
./.
====================
The/DT
most/JJS
famous/JJ
example/NN
is/VBZ
the/DT
fusion/NN
protein/NN
BCR-ABL/NN
,/,
which/WDT
is/VBZ
the/DT
target/NN
protein/NN
of/IN
the/DT
drug/NN
Gleevec/NN
treating/VBG
CML/NN
,/,
chronic/JJ
myeloid/JJ
leukemia/NN
(/(
Mauro/NN
and/CC
Druker/NN
,/,
2001/CD
)/)
./.
====================
CML/NN
is/VBZ
associated/VBN
in/IN
most/JJS
cases/NNS
with/IN
a/DT
chromosomal/JJ
translocation/NN
between/IN
chromosomes/NNS
9/CD
and/CC
22/CD
that/DT
creates/VBZ
the/DT
Philadelphia/NN
chromosome/NN
./.
====================
The/DT
BCR/NN
gene/NN
in/IN
chr22/NN
is/VBZ
fused/VBN
with/IN
the/DT
gene/NN
ABL/NN
in/IN
chr9/NN
,/,
so/RB
called/VBN
the/DT
t/NN
(/(
9/CD
;/:
22/CD
)/)
(/(
q34/NN
;/:
q11/NN
)/)
translocation/NN
./.
====================
The/DT
tyrosine/NN
kinase/NN
activity/NN
of/IN
ABL/NN
is/VBZ
constantly/RB
activated/VBN
by/IN
the/DT
BCR/NN
gene/NN
(/(
GTPase/NN
activator/NN
)/)
in/IN
the/DT
fusion/NN
protein/NN
,/,
resulting/VBG
in/IN
the/DT
rapid/JJ
cellular/JJ
mitosis/NN
and/CC
inability/NN
of/IN
the/DT
cell/NN
to/TO
perform/VB
apoptosis/NN
./.
====================
Gleevec/NN
inhibits/VBZ
the/DT
tyrosine/NN
kinase/NN
ability/NN
of/IN
the/DT
BCR-ABL/NN
fusion/NN
./.
====================
Gleevec/NN
is/VBZ
revolutionary/JJ
because/IN
it/PRP
proved/VBD
that/IN
molecular/JJ
targeting/VBG
works/NNS
in/IN
treating/VBG
cancer/NN
if/IN
the/DT
target/NN
is/VBZ
correctly/RB
chosen/NN
./.
====================
In/IN
AML/NN
(/(
acute/JJ
myeloid/JJ
leukemia/NN
)/)
patients/NNS
,/,
the/DT
RUNX1/NN
gene/NN
(/(
also/RB
known/VBN
as/IN
AML1/NN
or/CC
CBFA2/NN
)/)
is/VBZ
among/IN
the/DT
most/JJS
frequent/JJ
targets/NNS
of/IN
chromosomal/JJ
rearrangements/NNS
in/IN
human/JJ
leukemias/NNS
(/(
Mikhail/NN
et/FW
al./FW
,/,
2004/CD
)/)
./.
====================
More/RBR
than/IN
20/CD
cases/NNS
have/VBP
been/VBN
observed/VBN
by/IN
fluorescence/NN
in/FW
situ/FW
hybridization/NN
(/(
FISH/NN
)/)
analysis/NN
(/(
Mikhail/NN
et/FW
al./FW
,/,
2002/CD
)/)
./.
====================
Given/IN
the/DT
success/NN
of/IN
Gleevec/NN
and/CC
the/DT
recent/JJ
explosion/NN
of/IN
genomic/JJ
data/NNS
,/,
it/PRP
is/VBZ
quite/RB
plausible/JJ
to/TO
search/VB
the/DT
GenBank/NN
database/NN
looking/VBG
for/IN
chimeric/JJ
sequences/NNS
./.
====================
Fusion/NN
proteins/NNS
from/IN
chimeric/JJ
mRNAs/NNS
may/MD
serve/VB
as/IN
excellent/JJ
drug/NN
targets/NNS
in/IN
other/JJ
tumors/NNS
./.
====================
Function/NN
and/CC
expression/NN
analyses/NNS
of/IN
resultant/JJ
fusion/NN
proteins/NNS
are/VBP
essential/JJ
to/TO
find/VB
better/RBR
targets/NNS
as/IN
can/MD
be/VB
seen/VBN
in/IN
the/DT
example/NN
of/IN
the/DT
BCR-ABL/NN
case/NN
,/,
the/DT
combination/NN
of/IN
activator/NN
and/CC
kinase/NN
domains/NNS
./.
====================
Chimeric/JJ
sequences/NNS
can/MD
be/VB
generated/VBN
from/IN
other/JJ
mechanisms/NNS
./.
====================
Trans-splicing/VBG
can/MD
join/VB
two/CD
independently/RB
transcribed/VBN
mRNA/NN
sequences/NNS
at/IN
canonical/JJ
exon-exon/JJ
borders/NNS
./.
====================
Trans-splicing/VBG
was/VBD
first/JJ
detected/VBN
in/IN
vitro/FW
(/(
Solnick/NN
,/,
1985/CD
)/)
,/,
but/CC
subsequently/RB
shown/VBN
to/TO
occur/VB
in/IN
vivo/FW
in/IN
eukaryotes/NNS
(/(
Bonen/NNP
,/,
1993/CD
)/)
and/CC
mammals/NNS
(/(
Caudevilla/NN
et/FW
al./FW
,/,
1998/CD
)/)
./.
====================
Even/RB
though/IN
natural/JJ
trans-splicing/VBG
of/IN
pre-mRNAs/NNS
has/VBZ
been/VBN
regarded/VBN
to/TO
be/VB
a/DT
rare/JJ
event/NN
in/IN
mammals/NNS
,/,
human/JJ
estrogen/NN
receptor-^/JJ
gene/NN
is/VBZ
shown/VBN
to/TO
be/VB
trans-spliced/VBN
in/IN
addition/NN
to/TO
alternative/JJ
c/s-splicing/VBG
(/(
Flouriot/NN
et/FW
al./FW
,/,
2002/CD
)/)
./.
====================
Long/JJ
transcription/NN
across/IN
neighboring/JJ
genes/NNS
that/WDT
normally/RB
act/VBP
as/IN
independent/JJ
transcription/NN
units/NNS
has/VBZ
been/VBN
demonstrated/VBN
in/IN
several/JJ
cases/NNS
./.
====================
Cotranscription/NN
and/CC
intergenic/JJ
splicing/NN
lead/VBP
to/TO
a/DT
fusion/NN
mRNA/NN
./.
====================
Even/RB
though/IN
====================
its/PRP$
role/NN
is/VBZ
not/RB
known/VBN
,/,
it/PRP
certainly/RB
increases/VBZ
the/DT
diversity/NN
of/IN
the/DT
exon/NN
complement/NN
of/IN
the/DT
participating/VBG
genes/NNS
,/,
which/WDT
may/MD
contribute/VB
to/TO
gene/NN
evolution/NN
(/(
Communi/NNS
et/FW
al./FW
,/,
2001/CD
;/:
Finta/NN
and/CC
Zaphiropoulos/NN
,/,
2000/CD
)/)
./.
====================
Alberti/RB
and/CC
coworkers/NNS
developed/VBD
a/DT
screening/NN
procedure/NN
(/(
ISTReS/NNS
;/:
in/IN
silico/JJ
trans-splicing/VBG
retrieval/JJ
system/NN
)/)
to/TO
identify/VB
heterologous/JJ
,/,
spliced/VBN
mRNAs/NNS
with/IN
potential/JJ
origin/NN
from/IN
chromosomal/JJ
translocation/NN
,/,
mRNA/NN
frans-splicing/VBG
,/,
and/CC
multi-locus/JJ
transcription/NN
(/(
Romani/NNP
et/FW
al./FW
,/,
2003/CD
)/)
./.
====================
mRNA/NN
sequences/NNS
are/VBP
aligned/VBN
onto/IN
the/DT
genome/NN
by/IN
BLAST/NN
,/,
and/CC
applied/VBD
several/JJ
criteria/NNS
for/IN
filtering/VBG
and/CC
validation/NN
./.
====================
EST/NN
sequences/NNS
were/VBD
discarded/VBN
since/IN
the/DT
transcript/NN
direction/NN
is/VBZ
not/RB
annotated/VBN
in/IN
many/JJ
cases/NNS
./.
====================
EST/NN
sequence/NN
data/NNS
increases/VBZ
the/DT
transcriptome/JJ
diversity/NN
significantly/RB
./.
====================
For/IN
example/NN
,/,
61/CD
%/NN
of/IN
transcript/NN
variants/NNS
due/JJ
to/TO
alternative/JJ
splicing/NN
are/VBP
supported/VBN
only/RB
by/IN
EST/NN
sequences/NNS
./.
====================
Furthermore/RB
,/,
gene/NN
expression/NN
pattern/NN
can/MD
be/VB
inferred/VBN
by/IN
examining/VBG
the/DT
cDNA/NN
libraries/NNS
comprising/VBG
EST/NN
sequences/NNS
./.
====================
The/DT
NCI/NN
's/POS
CGAP/NN
(/(
cancer/NN
genome/NN
anatomy/NN
project/VB
)/)
is/VBZ
a/DT
major/JJ
source/NN
of/IN
public/JJ
EST/NN
sequences/NNS
,/,
and/CC
59/CD
%/NN
of/IN
human/JJ
cDNA/NN
libraries/NNS
in/IN
the/DT
dbEST/NN
are/VBP
related/JJ
to/TO
cancers/NNS
./.
====================
Therefore/RB
,/,
we/PRP
believe/VBP
that/IN
EST/NN
sequence/NN
data/NNS
is/VBZ
too/RB
valuable/JJ
to/TO
be/VB
discarded/VBN
especially/RB
when/WRB
the/DT
purpose/NN
of/IN
searching/VBG
for/IN
chimeric/JJ
sequences/NNS
is/VBZ
finding/NN
drug/NN
targets/NNS
to/TO
treat/VB
cancers/NNS
./.
====================
The/DT
problem/NN
of/IN
uncertain/JJ
read/VBN
direction/NN
can/MD
be/VB
alleviated/VBN
by/IN
using/VBG
the/DT
genome-based/VBN
EST/NN
clustering/NN
procedures/NNS
as/IN
in/IN
the/DT
UniGene/JJ
or/CC
the/DT
ECgene/NN
./.
====================
In/IN
this/DT
paper/NN
,/,
we/PRP
describe/VBP
a/DT
new/JJ
publicly/RB
available/JJ
database/NN
of/IN
chimeric/JJ
sequences/NNS
-ChimerDB-/NN
and/CC
the/DT
associated/VBN
navigator/NN
tools/NNS
./.
====================
Its/PRP$
coverage/NN
is/VBZ
substantially/RB
larger/JJR
than/IN
the/DT
ISTReS/NN
result/NN
because/IN
all/DT
mRNA/NN
and/CC
EST/NN
sequences/NNS
in/IN
the/DT
GenBank/NN
are/VBP
included/VBN
./.
====================
We/PRP
used/VBD
the/DT
July/NN
2003/CD
human/JJ
reference/NN
sequence/NN
(/(
UCSC/NN
version/NN
hg16/NN
)/)
that/WDT
is/VBZ
based/VBN
on/IN
NCBI/NN
Build/JJ
34/CD
./.
====================
The/DT
genome/NN
sequence/NN
was/VBD
downloaded/VBN
from/IN
the/DT
UCSC/NN
genome/NN
center/NN
./.
====================
mRNA/NN
and/CC
ESTs/NNS
sequences/NNS
are/VBP
obtained/VBN
from/IN
NCBI/NN
GenBank/NN
release/NN
138/CD
(/(
October/NN
15/CD
,/,
2003/CD
)/)
./.
====================
ESTs/NNS
in/IN
gbestNN.seq/NN
and/CC
mRNAs/NNS
in/IN
gbhtcNN/JJ
./.
====================
seq/NN
and/CC
gbpriNN.seq/NN
were/VBD
extracted/VBN
./.
====================
ECgene/NN
version/NN
1.1/CD
based/VBN
on/IN
hg16/NN
is/VBZ
used/VBN
throughout/IN
this/DT
work/NN
./.
====================
Reference/NN
sequences/NNS
were/VBD
not/RB
used/VBN
since/IN
their/PRP$
build/JJ
procedure/NN
specifically/RB
removes/VBZ
chimeric/JJ
sequences/NNS
./.
====================
mRNA/NN
and/CC
EST/NN
sequences/NNS
were/VBD
aligned/VBN
onto/IN
the/DT
human/JJ
genome/NN
using/VBG
the/DT
BLAT/NN
program/NN
(/(
Kent/JJ
,/,
2002/CD
)/)
./.
====================
We/PRP
used/VBD
the/DT
alignments/NNS
whose/WP$
percent/NN
identity/NN
is/VBZ
over/IN
93/CD
%/NN
./.
====================
BLAT/NN
output/NN
may/MD
contain/VB
many/JJ
overlapping/VBG
hits/VBZ
./.
====================
Segments/NNS
whose/WP$
overlap/JJ
</JJR
16/CD
bp/NN
are/VBP
treated/VBN
as/IN
independent/JJ
alignments/NNS
./.
====================
The/DT
longest/JJS
alignment/NN
is/VBZ
chosen/NN
among/IN
dependent/JJ
alignments/NNS
./.
====================
We/PRP
kept/VBP
chimeras/NNS
with/IN
two/CD
independent/JJ
segments/NNS
since/IN
other/JJ
chimeras/NNS
were/VBD
likely/RB
to/TO
derive/VB
from/IN
the/DT
random/JJ
co-ligation/NN
of/IN
unrelated/JJ
cDNA/NN
fragments/NNS
./.
====================
To/TO
retain/VB
reliable/JJ
chimeric/JJ
sequences/NNS
,/,
we/PRP
imposed/VBD
three/CD
additional/JJ
conditions/NNS
-/:
(/(
1/LS
)/)
the/DT
small/JJ
segment/NN
should/MD
cover/RB
over/IN
20/CD
%/NN
of/IN
the/DT
sequence/NN
,/,
(/(
2/CD
)/)
the/DT
large/JJ
segments/NNS
should/MD
cover/RB
less/RBR
than/IN
80/CD
%/NN
of/IN
the/DT
sequence/NN
,/,
and/CC
(/(
3/LS
)/)
aligned/VBD
sequences/NNS
from/IN
the/DT
two/CD
segments/NNS
should/MD
be/VB
over/IN
80/CD
%/NN
of/IN
the/DT
entire/JJ
sequence/NN
./.
====================
Segments/NNS
in/IN
the/DT
same/JJ
chromosome/NN
should/MD
be/VB
separated/VBN
farther/RB
than/IN
1/CD
Mbp/NN
./.
====================
Any/DT
alignment/NN
on/IN
chromosome/NN
M/NN
and/CC
random/JJ
assembly/NN
was/VBD
discarded/VBN
./.
====================
As/IN
a/DT
final/JJ
step/NN
,/,
each/DT
segment/NN
should/MD
have/VBP
more/RBR
than/IN
30/CD
bp/NN
overlap/IN
with/IN
an/DT
ECgene/NN
gene/NN
model/NN
./.
====================
Since/IN
the/DT
ECgene/NN
is/VBZ
based/VBN
on/IN
clustering/NN
EST/NN
sequences/NNS
of/IN
high/JJ
quality/NN
,/,
this/DT
removes/VBZ
unreliable/JJ
chimeras/NNS
from/IN
intergenic/JJ
or/CC
intronic/JJ
region/NN
of/IN
the/DT
genome/NN
./.
====================
Resultant/JJ
chimeric/JJ
sequences/NNS
are/VBP
grouped/VBN
according/VBG
to/TO
the/DT
ECgene/NN
ID/NN
of/IN
constituent/NN
segments/NNS
./.
====================
The/DT
contents/NNS
of/IN
the/DT
chimeric/JJ
sequence/NN
database/NN
can/MD
be/VB
====================
accessed/VBN
at/IN
the/DT
ChimerDB/NN
website/JJ
,/,
http/NN
:/:
//genome/DT
./.
====================
ewha.ac.kr/ECgene/ChimerDB/NN
./.
====================
Figure/NN
1/CD
is/VBZ
the/DT
summary/NN
table/JJ
of/IN
chimeric/JJ
sequences/NNS
./.
====================
Chromosome/NN
22/CD
contains/VBZ
573/CD
ECgene/NN
clusters/NNS
overlapping/VBG
with/IN
at/IN
least/JJS
one/CD
chimeric/JJ
sequence/NN
./.
====================
The/DT
table/JJ
shows/VBZ
number/NN
of/IN
chimeric/JJ
mRNA/NN
and/CC
EST/NN
sequences/NNS
./.
====================
It/PRP
should/MD
be/VB
noted/VBN
that/IN
many/JJ
chimeric/JJ
relationships/NNS
are/VBP
supported/VBN
by/IN
EST/NN
sequences/NNS
only/RB
as/IN
can/MD
be/VB
seen/VBN
in/IN
the/DT
second/JJ
and/CC
third/JJ
columns/NNS
./.
====================
Since/IN
the/DT
ECgene/NN
contains/VBZ
many/JJ
putative/JJ
genes/NNS
with/IN
no/DT
known/JJ
RefSeq/NN
,/,
we/PRP
provide/VBP
the/DT
number/NN
of/IN
RefSeq/NN
,/,
mRNA/NN
,/,
and/CC
EST/NN
sequences/NNS
to/TO
aid/VB
user/NN
's/POS
decision/NN
on/IN
reliability/NN
of/IN
the/DT
gene/NN
./.
====================
Clicking/VBG
the/DT
ECgene/NN
ID/NN
shows/VBZ
more/RBR
detailed/JJ
information/NN
of/IN
the/DT
ECgene/NN
cluster/NN
./.
====================
The/DT
BCR/NN
gene/NN
(/(
H22C1443/NN
)/)
contains/VBZ
12/CD
chimeric/JJ
mRNA/NN
and/CC
3/CD
chimeric/JJ
ESTs/NNS
,/,
and/CC
they/PRP
generate/VBP
four/CD
different/JJ
fusion/NN
genes/NNS
as/IN
listed/VBN
in/IN
the/DT
last/JJ
two/CD
columns/NNS
./.
====================
In/IN
addition/NN
to/TO
the/DT
well-known/JJ
ABL1/NN
gene/NN
,/,
we/PRP
have/VBP
three/CD
fusion/NN
partners/NNS
-/:
SLU7/NN
,/,
MTHFS/NN
,/,
and/CC
FGFR1/NN
./.
====================
Clicking/VBG
on/IN
'R123/CD
'/``
shows/VBZ
detailed/JJ
information/NN
on/IN
each/DT
chimeric/JJ
sequence/NN
as/IN
shown/VBN
in/IN
Figure/NN
2/CD
./.
====================
The/DT
table/JJ
summarizes/VBZ
how/WRB
the/DT
constituent/NN
genes/NNS
align/NN
on/IN
the/DT
chimeric/JJ
sequence/NN
./.
====================
It/PRP
also/RB
shows/VBZ
which/WDT
genes/NNS
are/VBP
joined/VBN
in/IN
each/DT
====================
chimeric/JJ
sequence/NN
./.
====================
The/DT
alignment/NN
information/NN
is/VBZ
helpful/JJ
in/IN
assessing/VBG
the/DT
reliability/NN
of/IN
the/DT
chimeric/JJ
sequence/NN
./.
====================
For/IN
example/NN
,/,
two/CD
EST/NN
sequences/NNS
(/(
BF380221/NN
,/,
BF094682/NN
)/)
giving/VBG
the/DT
BCR-SLU7/NN
fusion/NN
gene/NN
,/,
contain/VBP
unaligned/JJ
nucleotides/NNS
in/IN
the/DT
range/NN
of/IN
162-187/CD
bp/NN
./.
====================
Both/DT
ESTs/NNS
are/VBP
from/IN
the/DT
same/JJ
library/NN
of/IN
uterus-tumor/JJ
tissue/NN
./.
====================
All/DT
chimeric/JJ
mRNA/NN
sequences/NNS
generate/VBP
the/DT
BCR-ABL1/NN
fusion/NN
gene/NN
,/,
====================
and/CC
most/JJS
of/IN
them/PRP
(/(
except/IN
AB069693/NN
)/)
have/VBP
contiguous/JJ
alignments/NNS
between/IN
the/DT
two/CD
segments/NNS
./.
====================
We/PRP
also/RB
provide/VBP
a/DT
viewer/JJR
for/IN
genomic/JJ
alignment/NN
of/IN
the/DT
chimeric/JJ
sequences/NNS
./.
====================
Clicking/VBG
on/IN
the/DT
ECgene/NN
ID/NN
(/(
H22C1443/NN
)/)
in/IN
Figure/NN
2/CD
opens/NNS
a/DT
genome/NN
browser/JJR
as/IN
shown/VBN
in/IN
Figure/NN
3/CD
./.
====================
It/PRP
shows/VBZ
the/DT
ECgene/NN
structure/NN
and/CC
alignments/NNS
of/IN
chimeric/JJ
sequences/NNS
as/IN
custom/JJ
tracks/VBZ
./.
====================
ECgene/NN
structure/NN
includes/VBZ
transcript/NN
variants/NNS
due/JJ
to/TO
alternative/JJ
splicing/NN
./.
====================
Genomic/JJ
alignment/NN
of/IN
the/DT
chimeric/JJ
sequence/NN
often/RB
reveals/VBZ
the/DT
location/NN
of/IN
breakpoint/NN
in/IN
chromosomal/JJ
translocation/NN
./.
====================
We/PRP
find/VBP
three/CD
candidate/NN
breakpoints/NNS
for/IN
the/DT
BCR-ABL/NN
fusion/NN
mRNA/NN
,/,
indicated/VBD
as/IN
block/VBP
arrows/VBZ
in/IN
the/DT
picture/NN
./.
====================
Chromosomal/JJ
translocation/NN
in/IN
the/DT
Philadelphia/NN
chromosome/NN
seems/VBZ
to/TO
happen/VB
frequently/RB
near/JJ
the/DT
third/JJ
breakpoint/NN
since/IN
several/JJ
spliced/VBN
chimeric/JJ
mRNAs/NNS
appear/VBP
in/IN
that/DT
region/NN
./.
====================
Another/DT
benefit/NN
of/IN
genomic/JJ
alignment/NN
is/VBZ
that/DT
we/PRP
can/MD
examine/VB
the/DT
character/NN
of/IN
the/DT
fusion/NN
boundary/NN
./.
====================
The/DT
enlarged/JJ
view/NN
in/IN
the/DT
inset/NN
picture/NN
shows/VBZ
that/IN
the/DT
two/CD
ESTs/NNS
inferring/VBG
the/DT
BCR-SLU7/NN
have/VBP
different/JJ
alignment/NN
from/IN
other/JJ
chimeric/JJ
====================
sequences/NNS
./.
====================
The/DT
last/JJ
exon/NN
aligns/NNS
in/IN
the/DT
intron/NN
region/NN
of/IN
the/DT
gene/NN
,/,
which/WDT
strongly/RB
suggests/VBZ
artifactual/JJ
origin/NN
of/IN
two/CD
chimeric/JJ
sequences/NNS
./.
====================
Clicking/VBG
on/IN
the/DT
partner/NN
gene/NN
(/(
e.g/FW
./.
====================
ABL1/NN
gene/NN
,/,
H9C11979/NN
)/)
in/IN
Figure/NN
2/CD
shows/VBZ
similar/JJ
tables/NNS
and/CC
pictures/NNS
for/IN
the/DT
partner/NN
gene/NN
./.
====================
We/PRP
identified/VBD
688/CD
chimeric/JJ
mRNA/NN
and/CC
20,998/CD
chimeric/JJ
EST/NN
sequences/NNS
./.
====================
The/DT
number/NN
of/IN
chimeric/JJ
mRNAs/NNS
is/VBZ
approximately/RB
0.6/CD
%/NN
of/IN
118,034/CD
BLAT-aligned/JJ
mRNAs/NNS
./.
====================
Chimeric/JJ
ESTs/NNS
comprise/VBP
~0.4/CD
%/NN
of/IN
4,838,878/CD
BLAT-aligned/JJ
EST/NN
sequences/NNS
./.
====================
The/DT
ratio/NN
of/IN
chimeric/JJ
ESTs/NNS
is/VBZ
smaller/JJR
than/IN
that/DT
of/IN
mRNA/NN
probably/RB
because/IN
====================
short/JJ
EST/NN
sequences/NNS
have/VBP
less/RBR
chance/NN
of/IN
containing/VBG
the/DT
fusion/NN
boundary/NN
of/IN
the/DT
chimeric/JJ
sequence/NN
./.
====================
Chimeric/JJ
ESTs/NNS
consist/VBP
of/IN
4,235/CD
5/CD
'/``
ESTs/NNS
,/,
4,848/CD
3/CD
'/``
ESTs/NNS
,/,
and/CC
11,915/CD
ESTs/NNS
without/IN
read/JJ
direction/NN
./.
====================
The/DT
raw/JJ
database/NN
,/,
NCBI/NN
's/POS
dbEST/NN
,/,
contains/VBZ
2.47/CD
million/NN
5/CD
'/``
ESTs/NNS
,/,
1.78/CD
million/NN
3/CD
’/NN
ESTs/NNS
,/,
and/CC
1.18/CD
million/NN
undirected/JJ
ESTs/NNS
./.
====================
Portion/NN
of/IN
ESTs/NNS
without/IN
read/VBN
direction/NN
is/VBZ
rather/RB
high/JJ
in/IN
chimeric/JJ
sequences/NNS
,/,
which/WDT
may/MD
imply/VB
that/IN
chimeric/JJ
sequences/NNS
would/MD
contain/VB
more/RBR
artifactual/JJ
sequences/NNS
./.
====================
We/PRP
found/VBD
22,834/CD
ECgene/NN
clusters/NNS
overlapping/VBG
with/IN
any/DT
of/IN
21,686/CD
chimeric/JJ
sequences/NNS
./.
====================
797/CD
ECgenes/NNS
overlap/JJ
with/IN
both/CC
mRNA/NN
and/CC
EST/NN
chimers/NNS
./.
====================
473/CD
ECgenes/NNS
overlap/IN
with/IN
chimeric/JJ
mRNA/NN
sequences/NNS
,/,
and/CC
21,564/CD
ECgene/NN
clusters/NNS
are/VBP
related/JJ
to/TO
chimeric/JJ
EST/NN
sequences/NNS
with/IN
no/DT
mRNA/NN
chimers/NNS
./.
====================
Even/RB
though/IN
substantial/JJ
portion/NN
of/IN
chimeric/JJ
sequences/NNS
are/VBP
expected/VBN
from/IN
the/DT
artifacts/NNS
in/IN
cDNA/NN
library/NN
construction/NN
,/,
it/PRP
is/VBZ
obvious/JJ
that/DT
EST/NN
data/NNS
would/MD
contribute/VB
significantly/RB
to/TO
the/DT
content/NN
of/IN
chimeric/JJ
sequence/NN
database/NN
./.
====================
Total/JJ
number/NN
of/IN
the/DT
ECgene/NN
pairs/NNS
in/IN
the/DT
ChimerDB/NN
is/VBZ
75,455/CD
./.
====================
We/PRP
have/VBP
1,685/CD
pair/NN
relationships/NNS
being/VBG
supported/VBN
by/IN
mRNA/NN
chimers/NNS
,/,
147/CD
of/IN
which/WDT
are/VBP
also/RB
supported/VBD
by/IN
chimeric/JJ
EST/NN
sequences/NNS
./.
====================
Remaining/VBG
73,764/CD
pair/NN
relationships/NNS
are/VBP
supported/VBN
only/RB
by/IN
chimeric/JJ
EST/NN
sequences/NNS
./.
====================
This/DT
may/MD
imply/VB
that/IN
majority/NN
of/IN
EST/NN
chimers/NNS
are/VBP
from/IN
artifacts/NNS
or/CC
that/DT
the/DT
coverage/NN
by/IN
EST/NN
sequences/NNS
is/VBZ
much/RB
wider/JJR
./.
====================
It/PRP
is/VBZ
too/RB
early/JJ
to/TO
draw/VB
any/DT
conclusion/NN
at/IN
this/DT
point/NN
./.
====================
It/PRP
should/MD
be/VB
noted/VBN
that/IN
25/CD
chimeric/JJ
mRNAs/NNS
,/,
identified/VBD
by/IN
Alberti/NN
and/CC
coworker/NN
in/IN
2003/CD
,/,
are/VBP
removed/VBN
from/IN
the/DT
GenBank/NN
database/NN
now/RB
./.
====================
Only/RB
30/CD
chimeric/JJ
mRNAs/NNS
among/IN
55/CD
chimeric/JJ
RefSeq/NN
's/POS
remain/VBP
in/IN
the/DT
database/NN
./.
====================
This/DT
suggests/VBZ
that/IN
NCBI/NN
's/POS
RefSeq/NN
project/NN
is/VBZ
putting/JJ
substantial/JJ
efforts/NNS
to/TO
filter/NN
out/RP
artifactual/JJ
chimeric/JJ
sequences/NNS
./.
====================
Even/RB
chimeric/JJ
mRNAs/NNS
should/MD
be/VB
carefully/RB
examined/VBN
for/IN
their/PRP$
validity/NN
./.
====================
We/PRP
constructed/VBD
a/DT
database/NN
of/IN
chimeric/JJ
sequences/NNS
by/IN
examining/VBG
the/DT
genomic/JJ
alignment/NN
of/IN
mRNA/NN
and/CC
EST/NN
sequences/NNS
in/IN
the/DT
GenBank/NN
./.
====================
Including/VBG
EST/NN
sequences/NNS
greatly/RB
expands/VBZ
the/DT
scope/NN
of/IN
chimeric/JJ
sequences/NNS
even/RB
though/IN
it/PRP
inevitably/RB
includes/VBZ
many/JJ
artifactual/JJ
sequences/NNS
./.
====================
Instead/RB
of/IN
discarding/VBG
all/DT
EST/NN
sequences/NNS
,/,
our/PRP$
strategy/NN
is/VBZ
to/TO
filter/NN
out/RP
artifacts/NNS
at/IN
later/JJ
stages/NNS
./.
====================
Currently/RB
,/,
we/PRP
are/VBP
implementing/VBG
another/DT
filtering/JJ
scheme/NN
that/DT
selects/VBZ
====================
chimeric/JJ
sequences/NNS
whose/WP$
junction/NN
appears/VBZ
at/IN
exon-exon/JJ
border/NN
as/IN
in/IN
frans-splicing/VBG
./.
====================
Function/NN
and/CC
expression/NN
analyses/NNS
of/IN
resultant/JJ
fusion/NN
proteins/NNS
are/VBP
also/RB
in/IN
progress/NN
to/TO
identify/VB
better/RBR
targets/NNS
for/IN
example/NN
,/,
the/DT
combination/NN
of/IN
activator/NN
and/CC
kinase/NN
domains/NNS
in/IN
the/DT
BCR-ABL/NN
fusion/NN
./.
====================
Nevertheless/RB
,/,
the/DT
database/NN
and/CC
tools/NNS
provided/VBD
at/IN
the/DT
ChimerDB/NN
site/NN
should/MD
be/VB
a/DT
valuable/JJ
resource/NN
for/IN
finding/NN
drug/NN
targets/NNS
to/TO
treat/VB
cancers/NNS
./.
====================
